The autism spectrum disorder management market is anticipated to flourish at an average CAGR of 5.2% between 2023 and 2033. The market is expected to hold a market share of US$ 3.55 billion by 2033 while the market is likely to reach a value of US$ 2.14 billion in 2023.
Autism spectrum disorder can be defined as a neurodevelopment disorder or disability that is caused by rare or common inherited genetic variations, which is fueling the adoption of autism spectrum disorder management lately.
| Attributes | Details |
|---|---|
| Autism Spectrum Disorder Management Market CAGR (2023 to 2033) | 5.2% |
| Autism Spectrum Disorder Management Market Size (2023) | US$ 2.14 billion |
| Autism Spectrum Disorder Management Market Size (2033) | US$ 3.55 billion |
Patients suffering from autism spectrum disorder symptoms face difficulties in social interaction, daily activities, communication, and non-verbal interactions. Billions of people globally are being affected by Autistic Disorder, Asperger Syndrome, and Pervasive
Development disorders and a number of factors are anticipated to contribute to the market’s growth prospects, thereby bolstering a significant growth of the autism spectrum disorder management market during the forecast period.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
It is expected that the autism spectrum disorder management market is likely to have staggering growth and a number of factors are contributing to this rapid expansion of the market.
Rising Awareness About the Treatment: The rising prevalence of autism spectrum disorder or ASD globally, coupled with rising awareness about the condition and the available options for various treatment types of different diseases is the key factor expected to drive the autism spectrum disorder management market.
Growing Investments: The key players in the market are taking research and development initiatives for the launch of effective drugs to manage autistic disorders and are expected to fuel market growth.
Government Funding: Private and government funding is developing the infrastructure for autism spectrum disorder management. It is identified that there is a rise in the number of organizations overcoming communication problems and social challenges. NGO activities are anticipated to rise for making parents aware of the disorders, which will boost the growth of the market.
Although there are a number of growth factors prevailing in the market, it is identified that some aspects are likely to inhibit the expansion of the market size of autism spectrum disorder management.
High cost: It is witnessed that the treatment of autism spectrum disorder requires a high cost of treatment and diagnosis, which is expected to hinder the growth of the market.
Lack of Approved Drugs: It is identified that currently no drug can cure autism spectrum disorder or any of its associated core symptoms despite the increase in the need for effective clinical and drug trials for ASD.
It is witnessed that there are fundamental weaknesses in the methods, conceptual models in clinical translation research, and knowledge gaps, which will curb the growth in the coming years.
Principal Consultant
| Countries | Revenue Share % (2022) |
|---|---|
| United States | 37.6% |
| Germany | 7.6% |
| Japan | 3.2% |
| North America | 43.1% |
| Europe | 32.7% |
| Countries | CAGR % (2023 to 2033) |
|---|---|
| China | 6.3% |
| India | 5.2% |
| United Kingdom | 3.7% |
| Australia | 4.6% |
| Attributes | Details |
|---|---|
| Region | North America |
| Market Share | It is projected that North America is likely to hold the largest share of the autism spectrum disorder management market. Market Share Holding in 2022: 43.1% |
| Factors Responsible | The factors attributing to growth are:
|
| Attributes | Details |
|---|---|
| Region | Europe |
| Market Share | Europe is projected to hold the second-largest share of the autism spectrum disorder management market after North America and is likely to have substantial growth in the coming years. Market Share Holding in 2022: 32.7% |
| Factors Responsible | The factors attributing to expansion are:
|
| Category | By Indication Type |
|---|---|
| Leading Segment | Autistic Disorder |
| Market Share | 43.70% |
| Category | By Treatment Type |
|---|---|
| Leading Segment | Behavioral Approaches |
| Market Share | 32.40% |
Based on indication type, the autistic disorder segment leads the market as it held a market share of 43.70% in 2022. The treatment type category is dominated by the behavioral approaches segment as it held a market share of 32.40% in 2022.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The start-up companies are intensifying their focus on frequent innovations and indulging themselves in mergers and acquisitions to develop cost-effective, yet high-performance autism spectrum disorder management solutions.
Three Start-Ups to Watch for in the ASD Management Market
Key Take of the Biggies in the Autism Spectrum Disorder Management Market
The key players in the market are making efforts and continually indulging in joint ventures, collaboration & mergers amongst themselves to launch novel products for the treatment of autism by research institutes, and cost-effective treatment for the end-users.
Recent Developments
Some of the recent developments are:
The market is estimated to secure US$ 2.14 billion in 2023.
The rising prevalence of autism spectrum disorder or ASD globally and the research and development initiatives to launch effective drugs drive the market.
The high cost of treatment and diagnosis and the need for approved drugs restrain market growth.
The United States may witness significant growth in the market.
The United States, Japan, and China dominate the global market.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Product Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product Type, 2023 to 2033
5.3.1. Autistic Disorder
5.3.2. Asperger Syndrome
5.3.3. PDD-NOS
5.3.4. Other Pervasive Developmental Disorders
5.4. Y-o-Y Growth Trend Analysis By Product Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Product Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033
6.3.1. Behavioural Approaches
6.3.2. Early Intervention
6.3.3. Medication
6.3.4. Others
6.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By End-User , 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-User , 2023 to 2033
7.3.1. Hospitals
7.3.2. Education Counsellor Center
7.3.3. Others
7.4. Y-o-Y Growth Trend Analysis By End-User , 2018 to 2022
7.5. Absolute $ Opportunity Analysis By End-User , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Western Europe
8.3.4. Eastern Europe
8.3.5. South Asia and Pacific
8.3.6. East Asia
8.3.7. Middle East and Africa
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA.
9.2.1.2. Canada
9.2.2. By Product Type
9.2.3. By Treatment
9.2.4. By End-User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Product Type
9.3.3. By Treatment
9.3.4. By End-User
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Product Type
10.2.3. By Treatment
10.2.4. By End-User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Product Type
10.3.3. By Treatment
10.3.4. By End-User
10.4. Key Takeaways
11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. UK.
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Western Europe
11.2.2. By Product Type
11.2.3. By Treatment
11.2.4. By End-User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Product Type
11.3.3. By Treatment
11.3.4. By End-User
11.4. Key Takeaways
12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Poland
12.2.1.2. Russia
12.2.1.3. Czech Republic
12.2.1.4. Romania
12.2.1.5. Rest of Eastern Europe
12.2.2. By Product Type
12.2.3. By Treatment
12.2.4. By End-User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Product Type
12.3.3. By Treatment
12.3.4. By End-User
12.4. Key Takeaways
13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Bangladesh
13.2.1.3. Australia
13.2.1.4. New Zealand
13.2.1.5. Rest of South Asia and Pacific
13.2.2. By Product Type
13.2.3. By Treatment
13.2.4. By End-User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Product Type
13.3.3. By Treatment
13.3.4. By End-User
13.4. Key Takeaways
14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Product Type
14.2.3. By Treatment
14.2.4. By End-User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Product Type
14.3.3. By Treatment
14.3.4. By End-User
14.4. Key Takeaways
15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Product Type
15.2.3. By Treatment
15.2.4. By End-User
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Product Type
15.3.3. By Treatment
15.3.4. By End-User
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA.
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Product Type
16.1.2.2. By Treatment
16.1.2.3. By End-User
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Product Type
16.2.2.2. By Treatment
16.2.2.3. By End-User
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Product Type
16.3.2.2. By Treatment
16.3.2.3. By End-User
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Product Type
16.4.2.2. By Treatment
16.4.2.3. By End-User
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Product Type
16.5.2.2. By Treatment
16.5.2.3. By End-User
16.6. UK.
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Product Type
16.6.2.2. By Treatment
16.6.2.3. By End-User
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Product Type
16.7.2.2. By Treatment
16.7.2.3. By End-User
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Product Type
16.8.2.2. By Treatment
16.8.2.3. By End-User
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Product Type
16.9.2.2. By Treatment
16.9.2.3. By End-User
16.10. Poland
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Product Type
16.10.2.2. By Treatment
16.10.2.3. By End-User
16.11. Russia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Product Type
16.11.2.2. By Treatment
16.11.2.3. By End-User
16.12. Czech Republic
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Product Type
16.12.2.2. By Treatment
16.12.2.3. By End-User
16.13. Romania
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Product Type
16.13.2.2. By Treatment
16.13.2.3. By End-User
16.14. India
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Product Type
16.14.2.2. By Treatment
16.14.2.3. By End-User
16.15. Bangladesh
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Product Type
16.15.2.2. By Treatment
16.15.2.3. By End-User
16.16. Australia
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Product Type
16.16.2.2. By Treatment
16.16.2.3. By End-User
16.17. New Zealand
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Product Type
16.17.2.2. By Treatment
16.17.2.3. By End-User
16.18. China
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Product Type
16.18.2.2. By Treatment
16.18.2.3. By End-User
16.19. Japan
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Product Type
16.19.2.2. By Treatment
16.19.2.3. By End-User
16.20. South Korea
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Product Type
16.20.2.2. By Treatment
16.20.2.3. By End-User
16.21. GCC Countries
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Product Type
16.21.2.2. By Treatment
16.21.2.3. By End-User
16.22. South Africa
16.22.1. Pricing Analysis
16.22.2. Market Share Analysis, 2022
16.22.2.1. By Product Type
16.22.2.2. By Treatment
16.22.2.3. By End-User
16.23. Israel
16.23.1. Pricing Analysis
16.23.2. Market Share Analysis, 2022
16.23.2.1. By Product Type
16.23.2.2. By Treatment
16.23.2.3. By End-User
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Product Type
17.3.3. By Treatment
17.3.4. By End-User
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Curemark, LLC
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Alembic Pharmaceuticals Limited
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Yamo Pharmaceuticals
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. PaxMedica
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. F. Hoffmann-La Roche Ltd
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. Aurobindo Pharma Ltd.
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Otsuka Holdings Co. Ltd.
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. Janssen Pharmaceuticals, Inc.
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Teva Pharmaceutical Industries Ltd.
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. H. Lundbeck A/S
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Autism Spectrum Disorder Management Market
